Online inquiry

IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2539MR)

This product GTTS-WQ2539MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2539MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10703MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ6794MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ14331MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ14791MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ1819MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ5415MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ1558MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ7700MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW